March 4, 2016
Gilead Sciences’s hepatitis C treatments, Sovaldi (sofosbuvir) and Harvoni (ledipasvir + sofosbuvir), will see their prices slashed by 31.7% in April under a new special re-pricing rule for fast-growing blockbusters , the Ministry of Health, Labor and Welfare (MHLW) announced...read more